한글목차

비뇨생식기 치료제 세계 시장 규모는 2030년까지 410억 달러에 달할 것으로 전망

2023년 348억 달러로 추정되는 비뇨생식기 치료제 세계 시장은 2023-2030년의 분석 기간 동안 연평균 2.4% 성장하여 2030년에는 410억 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 비뇨기과 부문은 CAGR 3.2%를 기록하여 분석 기간 종료 시점에 107억 달러에 도달할 것으로 예상됩니다. 항감염제 부문은 분석 기간 동안 CAGR 1.6%로 성장할 것으로 추정됩니다.

미국 시장은 94억 달러로 추정, 중국은 CAGR 4.2%로 성장 전망

미국 비뇨생식기 치료제 시장은 2023년 94억 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 79억 달러 규모에 도달할 것으로 예상되며, 2023-2030년의 분석 기간 동안 4.2%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 1.3%와 2.1%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 연평균 1.6%의 성장률을 보일 것으로 예상됩니다.

세계 비뇨생식기 치료제 시장 - 주요 동향 및 촉진요인 요약

고령화는 비뇨생식기 치료제 수요에 어떤 영향을 미치고 있는가?

비뇨생식기 치료제 세계 시장은 요실금, 전립선 질환, 요로 감염 등 노화와 관련된 비뇨기계 질환이 보편화됨에 따라 고령화 사회의 영향을 크게 받고 있습니다. 노인들은 이러한 질환에 걸리기 쉬우며, 종종 장기적인 의학적 관리가 필요합니다. 이러한 인구 통계학적 변화는 고령화 인구가 빠르게 증가하고 있는 선진국에서 특히 두드러집니다. 이에 따라 호르몬 대체 요법 및 표적 치료제를 포함한 비뇨생식기 치료제에 대한 수요가 증가할 것으로 예상되며, 주요 기업들은 이 분야의 제품 공급을 확대하고 있습니다.

약물 전달의 혁신이 비뇨생식기 치료에 중요한 이유는 무엇인가?

약물 전달 시스템의 혁신은 투약 방법을 바꾸고 환자의 결과와 편의성을 개선하고 있습니다. 서방형 제제와 경피 패치는 효과가 더 오래 지속되고 투여 빈도를 줄이기 위해 개발되어 만성 질환을 관리하는 환자에게 도움이 될 수 있습니다. 주사제 및 이식형 장치도 특히 호르몬 상태 및 전립선 건강 관리에서 인기를 끌고 있습니다. 이러한 혁신은 환자가 약물 복용 일정을 지키고, 치료 효과를 높이고, 환자의 삶의 질을 향상시키는 문제를 해결하는 데 있어 매우 중요합니다.

여성 건강이 시장 확대에서 차지하는 역할은?

여성 건강은 요로 감염, 폐경, 골반장기탈출증과 같은 증상에 대한 전문적인 치료가 필요하기 때문에 비뇨생식기 치료제 시장의 중요한 촉진제입니다. 여성 건강 문제에 대한 인식이 높아지고 의료 서비스 제공업체가 맞춤형 치료 옵션을 우선시함에 따라 이러한 증상을 치료하는 약물에 대한 수요가 증가하고 있습니다. 여성에 특화된 치료와 표적 치료의 개발은 특히 많은 지역에서 아직 충분히 치료되지 않은 생식 및 호르몬 치료와 관련된 분야에서 시장에 새로운 기회를 제공합니다.

비뇨생식기 치료제 시장의 성장 촉진요인은 무엇인가?

비뇨생식기 치료제 시장의 성장을 가속하는 요인은 고령화, 약물 전달 시스템의 발전, 여성 건강에 대한 관심 증가 등입니다. 노화와 관련된 비뇨생식기 질환의 유병률 증가는 혁신적이고 편리한 전달 방법에 대한 환자들의 요구와 결합하여 이 분야의 제품 혁신을 촉진하고 있습니다. 또한, 여성 건강에 대한 인식과 우선순위가 높아지면서 전문적인 치료에 대한 수요가 증가하여 시장 성장을 더욱 촉진하고 있습니다. 이러한 요인들로 인해 비뇨생식기 치료제 시장은 다양한 계층의 중요한 건강 수요를 충족시키며 꾸준히 성장할 것으로 예상됩니다.

조사 대상 기업 예시(총 42건)

• Astellas Pharma, Inc.
• Bayer AG
• Daiichi Sankyo Co.
• GlaxoSmithKline PLC
• Otsuka Pharmaceutical Co.
• Pfizer, Inc.
• Sanofi SA
• Shandong Luoxin Pharmaceutical Group Stock co.
• Yichang HEC Changjiang Pharmaceutical Company Limited

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 스페인
• 러시아
• 기타 유럽
• 아시아태평양
• 호주
• 인도
• 한국
• 기타 아시아태평양
• 라틴아메리카
• 아르헨티나
• 브라질
• 멕시코
• 기타 라틴아메리카
• 중동
• 이란
• 이스라엘
• 사우디아라비아
• 아랍에미리트(UAE)
• 기타 중동
• 아프리카

제4장 경쟁

영문목차

Global Genitourinary Drugs Market to Reach US$41.0 Billion by 2030

The global market for Genitourinary Drugs estimated at US$34.8 Billion in the year 2023, is expected to reach US$41.0 Billion by 2030, growing at a CAGR of 2.4% over the analysis period 2023-2030. Urologicals, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$10.7 Billion by the end of the analysis period. Growth in the Anti-Infectives segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.4 Billion While China is Forecast to Grow at 4.2% CAGR

The Genitourinary Drugs market in the U.S. is estimated at US$9.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$7.9 Billion by the year 2030 trailing a CAGR of 4.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Genitourinary Drugs Market - Key Trends & Drivers Summarized

How Is the Aging Population Impacting Demand for Genitourinary Drugs?

The global genitourinary drugs market has been significantly influenced by the aging population, as age-related genitourinary conditions such as urinary incontinence, prostate disorders, and urinary tract infections become more prevalent. Older adults are more susceptible to these conditions, which often require long-term medical management. This demographic shift is particularly prominent in developed countries, where the aging population is rising rapidly. As a result, demand for genitourinary medications, including hormone replacement therapies and targeted drugs, is expected to increase, leading pharmaceutical companies to expand their offerings in this sector.

Why Are Innovations in Drug Delivery Important for Genitourinary Treatments?

Innovations in drug delivery systems are transforming the way genitourinary drugs are administered, improving patient outcomes and convenience. Extended-release formulations and transdermal patches are being developed to offer longer-lasting effects and reduce the frequency of dosage, which is beneficial for patients managing chronic conditions. Injectable and implantable devices are also gaining popularity, particularly in managing hormonal conditions and prostate health. These innovations are critical as they address challenges in patient adherence to medication schedules, enhancing treatment efficacy and patient quality of life.

What Role Does Women’s Health Play in Market Expansion?

Women's health is a significant driver in the genitourinary drugs market, as conditions like urinary tract infections, menopause-related symptoms, and pelvic organ prolapse require specialized treatments. Demand for drugs that cater to these conditions is increasing as awareness of women’s health issues grows and healthcare providers prioritize tailored treatment options. The development of female-specific treatments and targeted therapies has opened new opportunities within the market, particularly in areas related to reproductive health and hormonal therapy, which remain underserved in many regions.

What Drives the Growth of the Genitourinary Drugs Market?

The growth in the genitourinary drugs market is driven by factors including an aging population, advancements in drug delivery systems, and rising focus on women’s health. Increased prevalence of age-related genitourinary conditions, coupled with patient demand for innovative, convenient delivery methods, is driving product innovation in this sector. Additionally, heightened awareness and prioritization of women’s health have spurred demand for specialized treatments, further supporting market growth. These factors position the genitourinary drugs market for steady expansion as it addresses critical health needs across different demographics.

Select Competitors (Total 42 Featured) -

• Astellas Pharma, Inc.
• Bayer AG
• Daiichi Sankyo Co., Ltd.
• GlaxoSmithKline PLC
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer, Inc.
• Sanofi SA
• Shandong Luoxin Pharmaceutical Group Stock co., ltd.
• Yichang HEC Changjiang Pharmaceutical Company Limited

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Genitourinary Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Urinary Tract and Kidney Disorders Driving Demand
  • Growth in Awareness and Diagnosis of Genitourinary Conditions
  • Rising Demand for Targeted Therapies in Prostate Cancer and Bladder Disorders
  • Expansion of Therapeutics for Overactive Bladder and Incontinence Management
  • Surge in Use of Hormonal Therapies in Genitourinary Cancer Treatment
  • Advancements in Drug Delivery Systems for Enhanced Patient Compliance
  • Growing Adoption of Combination Therapies for Effective Disease Management
  • Rising Focus on Minimally Invasive and Non-Surgical Treatment Options
  • Expansion of Genitourinary Drug Markets in Aging Populations
  • Increased Research and Development in Urology-Specific Medications
  • Growth in Biopharma Collaborations for Genitourinary Disease Treatments
  • Focus on Improving Quality of Life for Patients with Chronic Genitourinary Conditions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Genitourinary Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Genitourinary Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Genitourinary Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Genitourinary Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Urologicals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Urologicals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Urologicals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Anti-Infectives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Gynecological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Gynecological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Gynecological by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Renal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Renal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Renal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Sexually Transmitted Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Sexually Transmitted Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Sexually Transmitted Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Cervical Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Erectile Dysfunction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Erectile Dysfunction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: World 16-Year Perspective for Erectile Dysfunction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: World 16-Year Perspective for Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Urinary Tract Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Urinary Tract Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: World 16-Year Perspective for Urinary Tract Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Genitourinary Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• JAPAN
  • Genitourinary Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• CHINA
  • Genitourinary Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: China 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: China 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• EUROPE
  • Genitourinary Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Genitourinary Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Genitourinary Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Genitourinary Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• FRANCE
  • Genitourinary Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: France 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: France 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• GERMANY
  • Genitourinary Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Germany 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Germany 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Italy Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Italy 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Italy 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Genitourinary Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 98: UK Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: UK Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: UK 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 101: UK Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: UK Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: UK 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 104: Spain Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Spain Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Spain 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 107: Spain Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Spain Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Spain 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 110: Russia Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Russia Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Russia 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 113: Russia Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Russia Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Russia 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Rest of Europe Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Rest of Europe 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Rest of Europe Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Rest of Europe 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Genitourinary Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Genitourinary Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 123: Asia-Pacific Historic Review for Genitourinary Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: Asia-Pacific 16-Year Perspective for Genitourinary Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Asia-Pacific Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Asia-Pacific 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Asia-Pacific Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Asia-Pacific 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Genitourinary Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 131: Australia Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Australia Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Australia 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 134: Australia Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Australia Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Australia 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• INDIA
  • Genitourinary Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 137: India Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: India Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: India 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 140: India Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: India Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: India 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 143: South Korea Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: South Korea Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: South Korea 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 146: South Korea Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: South Korea Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: South Korea 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 149: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Rest of Asia-Pacific Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Rest of Asia-Pacific 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 152: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Rest of Asia-Pacific Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Rest of Asia-Pacific 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Genitourinary Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 155: Latin America Recent Past, Current & Future Analysis for Genitourinary Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 156: Latin America Historic Review for Genitourinary Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Latin America 16-Year Perspective for Genitourinary Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 158: Latin America Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Latin America Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Latin America 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 161: Latin America Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Latin America Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Latin America 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 164: Argentina Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Argentina Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Argentina 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 167: Argentina Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Argentina Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Argentina 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 170: Brazil Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Brazil Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: Brazil 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 173: Brazil Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Brazil Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: Brazil 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 176: Mexico Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Mexico Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: Mexico 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 179: Mexico Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Mexico Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: Mexico 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 182: Rest of Latin America Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Rest of Latin America Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Rest of Latin America 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 185: Rest of Latin America Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Rest of Latin America Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Rest of Latin America 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Genitourinary Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 188: Middle East Recent Past, Current & Future Analysis for Genitourinary Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 189: Middle East Historic Review for Genitourinary Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Middle East 16-Year Perspective for Genitourinary Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 191: Middle East Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Middle East Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Middle East 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 194: Middle East Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Middle East Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Middle East 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 197: Iran Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Iran Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Iran 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 200: Iran Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Iran Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Iran 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 203: Israel Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Israel Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Israel 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 206: Israel Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Israel Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Israel 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 209: Saudi Arabia Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Saudi Arabia Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Saudi Arabia 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 212: Saudi Arabia Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Saudi Arabia Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Saudi Arabia 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 215: UAE Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: UAE Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: UAE 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 218: UAE Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 219: UAE Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 220: UAE 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 221: Rest of Middle East Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 222: Rest of Middle East Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 223: Rest of Middle East 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 224: Rest of Middle East Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 225: Rest of Middle East Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 226: Rest of Middle East 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030
• AFRICA
  • Genitourinary Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 227: Africa Recent Past, Current & Future Analysis for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 228: Africa Historic Review for Genitourinary Drugs by Type - Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 229: Africa 16-Year Perspective for Genitourinary Drugs by Type - Percentage Breakdown of Value Sales for Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy and Other Types for the Years 2014, 2024 & 2030
  • TABLE 230: Africa Recent Past, Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 231: Africa Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 232: Africa 16-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract Infection and Other Indications for the Years 2014, 2024 & 2030

IV. COMPETITION